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Abstract
Background: In the analysis of survival data for cancer patients, the problem of competing risks is often ignored.
Competing risks have been recognized as a special case of time-to-event analysis. The conventional techniques for
time-to-event analysis applied in the presence of competing risks often give biased or uninterpretable results.
Methods: Using a prospectively collected administrative health care database in a single institution, we
identified patients diagnosed with stage III or IV primary epithelial ovarian, tubal, and peritoneal cancers with
minimal residual disease after primary cytoreductive surgery between 1995 and 2012. Here, we sought to
evaluate whether intraperitoneal chemotherapy outperforms intravenous chemotherapy in the presence of
competing risks. Unadjusted and multivariable subdistribution hazards models were applied to this database
with two types of competing risks (cancer-specific mortality and other-cause mortality) coded to measure the
relative effects of intraperitoneal chemotherapy.
Results: A total of 1263 patients were recruited as the initial cohort. After propensity score matching, 381 patients in
each arm entered into final competing risk analysis. Cumulative incidence estimates for cancer-specific mortality were
statistically significantly lower (p = 0.017, Gray test) in patients receiving intraperitoneal chemotherapy (5-year estimates,
34.5 %; 95 % confidence interval [CI], 29.5–39.6 %, and 10-year estimates, 60.7 %; 95 % CI, 52.2–68.0 %) versus
intravenous chemotherapy (5-year estimates, 41.3 %; 95 % CI, 36.2–46.3 %, and 10-year estimates, 67.5 %, 95 % CI,
61.6–72.7 %). In subdistribution hazards analysis, for cancer-specific mortality, intraperitoneal chemotherapy
outperforms intravenous chemotherapy (Subdistribution hazard ratio, 0.82; 95 % CI, 0.70–0.96) after correcting
other covariates.
Conclusions: In conclusion, results from this comparative effectiveness study provide supportive evidence for previous
published randomized trials that intraperitoneal chemotherapy outperforms intravenous chemotherapy even eliminating
the confounding of competing risks. We suggest that implementation of competing risk analysis should be highly
considered for the investigation of cancer patients who have medium to long-term follow-up period.
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Background
Ovarian cancer is the sixth most common tumor in
women. More than 200,000 new cases are diagnosed
each year worldwide. Each year, it constitutes 4 % of all
cancers diagnosed in women, and there are 6.6 new
cases per 100,000 women per year [1]. Epithelial ovarian
cancer takes the predominant 90 % of cases among ovarian
cancer patients.
Epithelial ovarian cancer typically spreads by intraperi-
toneal seeding or direct invasion or through the lymphatic
and vascular circulation. Among the spreading routes,
peritoneal spreading is the most common route of
dissemination, and stage III disease is associated at
best with a 5-year survival rate of approximately 32–47 %
[2]. Therefore, it is reasonable to consider the intra-
peritoneal chemotherapy for this disease entity [3].
Intraperitoneal chemotherapy has been investigated
for several decades, and there have been three large-
scale randomized trials conducted in the US, all of
which showed overall and/or progression-free survival
benefit [4–6].
Most published studies for ovarian cancer use the time
to some disease events as their primary outcome and
hence, statistical methods developed for survival data are
usually applied. Established methods for estimating and
modelling these include the Kaplan–Meier estimator of
the survival function and the Cox proportional hazards
model for the hazard function [7, 8] An important
assumption of these established survival analytical
methods is that censoring is ‘independent’ [9]. However,
in some cases, several causes of failure are possible but
the occurrence of one event precludes the occurrence of
the other events (i.e., when failures are different causes
of death, only the first one can be observed). This
situation is known as competing risks. In a competing
risk situation, standard techniques for survival analysis
may lead to incorrect and biased results [10, 11]. In usual
condition, ovarian cancer often presents a protracted
disease course, and it is not uncommon to see a patient
dies of other causes (e.g., heart failure and stroke), which
precludes the occurrence of cancer-specific death.
In the current work, we conducted a competing risk
analysis to investigate the therapeutic effects of intraper-
itoneal chemotherapy on stage III-IV epithelial ovarian,
tubal, and peritoneal cancer with minimal residual
disease using an administrative health care database
constructed in a single tertiary care institution.
Methods
Study population
The study entailed a retrospective analysis of prospectively
collected demographic, tumor profile, treatment, and co-
morbidity data, linking electronic data sources, including
the cancer registry, administrative and clinical databases,
and surgery records of consecutive patients with stage III
or IV primary epithelial ovarian, tubal, and peritoneal
cancers with minimal residual disease after primary cytor-
eductive surgery between January 1995 and December
2012. The standard patient informed consent for retrieval
of personal information at the institution included an
emphasized section describing the purpose of the study.
This study was approved by the Institutional Review
Board of Taipei Veterans General Hospital. The proce-
dures used in this study were in accordance with the
guidelines of the Helsinki Declaration on human
experimentation.
Primary cytoreductive surgery and front-line chemotherapy
The standard cytoreductive surgery included total
hysterectomy, bilateral salpingo-oophorectomy, infracolic
omentectomy, and cytoreduction of all tumor nodules to
a size of 1 cm or less in the greatest dimension.
Courses of front-line chemotherapy were repeated
every 3 weeks for a total of six cycles, provided the
serum creatinine concentration was less than or equal to
2.0 mg/dl, the white-cell count was higher than 3000/
mm3, and the platelet count was higher than 80,000/mm3.
Dosing schedules for intraperitoneal chemotherapy were
either platinum-based or taxane-based. For platinum-based
intraperitoneal chemotherapy, cisplatin at 100 mg/m2 or
carboplatin at AUC 5 or 6 via Tenckhoff tubes was admin-
istered. For taxane-based intraperitoneal chemotherapy,
protocol for GOG 172 was followed.6
For intravenous chemotherapy, both taxane (175 mg/m2)
plus cisplatin (dosed at 50 mg/m2) or carboplatin (AUC= 5
or 6) were administered every 3 weeks for a total of six
cycles.
In each cycle of chemotherapy, patients received physical
examination, complete blood count, biochemical profiles,
CA-125, and 24-h urine collection for measurement of
clearance of creatinine. In the absence of clinical
evidence of tumor progression, tumor evaluation by
image studies including chest film, whole abdominal
sonography, and CT scan (or MRI) was performed
after six cycles of chemotherapy.
Statistical analyses
Continuous variables are presented as mean (± standard
deviations) and were compared using Student’s unpaired
t-test. Categorical variables are presented as counts and
percentages and were compared with the χ2 test when
appropriate (expected frequency > 5). Otherwise, Fisher’s
exact test was used. Overall survival duration was calcu-
lated from disease diagnosis to event occurrence or last
follow-up. Patients who succumbed to cancer-related
death were classified as cancer-specific mortality (CSM),
while patients who succumbed to other causes were
classified as other-cause mortality (OCM).
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Our statistical analyses consisted of two steps. In the
first step, we attempted to adjust for the selection bias
inherent in observational data by applying propensity
score matching to balance the measured covariates be-
tween the intravenous and intraperitoneal chemotherapy
group. The propensity score is a summary confounder
score that is modeled using the exposure or treatment as
the dependent variable [12]. The propensity to receive
intraperitoneal chemotherapy was calculated using a
multivariable logistic regression model that adjusted to
age at diagnosis, FIGO stage, tumor grade, histology,
Charlson comorbidity index, and GOG performance
score. We used the nearest neighbor matching with a
caliper width of 0.2 of the standardized deviation of the
logit to match cases. This optimizes the matching with
minimal residual bias and highest precision [13]. Co-
variate balance was evaluated using standardized
differences of means (SDM), with SDM of < 0.1
(corresponding to <10 % difference between the arms)
indicative of acceptable balance [14].
In the second step of analyses, competing risks analyses
were conducted based on the propensity score-matched
cohort. The crude cumulative incidence function were es-
timated for each type of competing risk using the method
of Kalbfleisch and Prentice [15, 16] Cumulative incidence
plots were used to graphically depict CSM and OCM
rates. Statistical significance of differences in survival rates
was assessed with the Gray test [17] Furthermore, we in-
vestigated differences in each cause of mortality (for CSM
and OCM, respectively) using subdistribution hazard
Table 1 Descriptive characteristics of patients treated with intravenous vs. intraperitoneal chemotherapy for stage III-IV epithelial ovarian,
tubal, and peritoneal cancer with minimal residual disease between 1995 and 2012 (n = 1263)
Initial cohort (n = 1263) Propensity score-matched cohort (n = 548)
intravenous intraperitoneal SDM intravenous intraperitoneal SDMa
n = 847 n = 416 n = 381 n = 381
Characteristics (71.4 %) (28.6 %) (50 %) (50 %)
Age (y, mean) 54.3 52.6 0.017 52.7 52.6 0.002
Stage (%)
III 671 (90.1 %) 267 (89.6 %) 0.014 254 (92.7 %) 252 (92.0 %) 0.013
IV 74 (9.9 %) 31 (10.4 %) −0.020 20 (7.3 %) 22 (8.0 %) −0.021
Grade (%)
1 119 (16.0 %) 43 (14.4 %) 0.011 33 (12.0 %) 37 (13.5 %) −0.021
2 429 (57.6 %) 180 (60.4 %) −0.008 178 (65.0 %) 176 (64.2 %) 0.017
3 197 (26.4 %) 75 (25.2 %) 0.009 63 (23.0 %) 61 (22.2 %) 0.011
Histologic subtype (%)
Serous 371 (49.8 %) 145 (48.7 %) 0.016 142 (51.8 %) 140 (51.1 %) 0.006
Mucinous 75 (10.1 %) 26 (8.7 %) 0.014 21 (7.7 %) 24 (8.8 %) −0.016
Clear cell 109 (14.6 %) 41 (13.8 %) 0.007 41 (15.0 %) 38 (13.9 %) 0.014
Endometrioid 83 (11.1 %) 45 (15.1 %) −0.037 48 (17.5 %) 45 (16.4 %) 0.010
Mixed or othersa 107 (14.4 %) 41 (13.8 %) 0.009 22 (8.0 %) 27 (9.9 %) −0.019
Front-line regimen (%)
Paclitaxel based 661 (88.8 %) 259 (81.2 %) 0.074 245 (89.4 %) 248 (90.5 %) −0.008
Not paclitaxel based 84 (11.3 %) 39 (13.1 %) −0.017 29 (10.6 %) 26 (9.5 %) 0.009
Consolidation chemotherapy (%)
No 622 (83.5 %) 242 (83.9 %) −0.007 202 (73.7 %) 203 (74.1 %) −0.005
Yes 123 (16.5 %) 56 (16.1 %) 0.008 72 (26.3 %) 71 (25.9 %) 0.006
GOG performance status
≤ 1 649 (87.1 %) 250 (83.9 %) 0.026 241 (88.0 %) 239 (87.2 %) 0.003
≥ 2 96 (12.9 %) 48 (16.1 %) −0.027 33 (12.0 %) 35 (12.8 %) −0.006
Charlson comorbidity index (%)
0 637 (85.5 %) 231 (77.5 %) 0.103 223 (81.4 %) 219 (80.0 %) 0.008
≥ 1 108 (14.5 %) 67 (22.5 %) −0.146 51 (18.6 %) 55 (20.0 %) −0.014
Abbreviations SDM standardized difference of means
aOthers histology include: undifferentiated and unclassified epithelial carcinoma
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ratios estimated through Fine and Gray proportional haz-
ards regression [18] Censoring time was set at December
31, 2012. The dataset supporting the conclusions of this
article is listed in Additional file 1.
Finally, we performed a sensitivity analysis based on
different sample size when extreme values of the
propensity score were trimmed at different levels - a
procedure shown to partly compensate for unobserved
confounding [19].
All tests were performed two sided at the 5 % signifi-
cance level. Statistical analyses were performed with
IBM SPSS Statistics (version 20.0, IBM, Armonk, NY),
and R software (version 2.15, R Foundation for Statistical
Computing, Vienna, Austria) using the cmprsk, survival,
and Matching packages [20].
Results
A total of 1263 patients were recruited as the initial
cohort. The patients’ baseline clinical characteristics of the
initial cohort are summarized in the left part of Table 1. In
terms of standardized difference of means, there were sig-
nificant differences in age, stage, grade, histologic subtype,
proportion of front-line regimen, GOG performance sta-
tus, and Charlson comorbidity score. However, after
propensity score-matching (summarized at right part
of Table 1), the standardized difference of means in
all the baseline clinical characteristics was less than
10 %, which indicates a high degree of similarity in
the distribution of these covariates, with equal number of
381 patients receiving intravenous chemotherapy and in-
traperitoneal chemotherapy, respectively. The propensity
score-matched cohort forms the basis for the following
analyses. The median follow-up time for this cohort was
8.4 years.
Figure 1 shows the estimates and curves of cumulative
incidence function stratified by CSM and OCM, and
sub-stratified by type of chemotherapy (intravenous vs.
intraperitoneal chemotherapy). Cumulative incidence
estimates for CSM were statistically significantly lower
(p = 0.017, Gray test) in patients receiving intraperitoneal
chemotherapy (5-year estimates, 34.5 %; 95 % confidence
interval [CI], 29.5–39.6 %, and 10-year estimates, 60.7 %;
95 % CI, 52.2–68.0 %) versus intravenous chemotherapy
(5-year estimates, 41.3 %; 95 % CI, 36.2–46.3 %, and
10-year estimates, 67.5 %, 95 % CI, 61.6–72.7 %). In
contrast, cumulative incidence estimates for OCM were
comparable (p = 0.705, Gray test) between patients receiv-
ing intraperitoneal chemotherapy (5-year estimates, 6.8 %;
95 % CI, 4.4–9.8 %, and 10-year estimates, 21.8 %, 95 %
CI, 16.5–27.5 %) and receiving intravenous chemotherapy
Fig. 1 Curves for cumulative incidence function stratified by CSM and OCM, and further sub-stratified by iv or ip chemotherapy. Abbreviations: iv,
intravenous chemotherapy; ip, intraperitoneal chemotherapy
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(5-year estimate, 4.5 %; 95 % CI, 2.9–7.6 %, and 10-year
estimate, 26.7 %; 95 % CI, 20.6–32.6 %).
Because ovarian cancer is now considered as a hetero-
geneous disease in which histologic phenotypes correlate
with distinct genetic events, therefore we present cumu-
lative incidence estimates for each histologic subtypes.
For each histologic subtype, there remains a significant
difference for CSM between intravenous chemotherapy
and intraperitoneal chemotherapy. However, for OCM,
there is no difference between intravenous chemother-
apy and intraperitoneal chemotherapy (Fig. 2).
In conventional survival analysis, application of Cox
proportional hazards regression uses multivariable
hazard ratios can account for confounding. Nonetheless,
Cox regression may lead to biased effect estimates in the
presence of competing risks [21]. Hence, we next con-
ducted unadjusted and adjusted regression modelling
proposed by Fine and Gray in the presence of competing
risks [18]. Unadjusted and adjusted subdistribution
hazard ratios for CSM and OCM are given in Table 2.
For CSM, several factors demonstrate statistically signifi-
cant which include stage, grade, histology, and type of
chemotherapy in the univariable analysis. However, after
multivariable regression modelling, only some factors
remain as an independent risk factor, including stage
(IV vs. III, subdistribution hazard ratio [SDHR], 2.66;
95 % CI, 1.47–4.81]), grade (grade 3 vs. grade 1, SDHR,
1.89; 95 % CI, 1.04–3.43), histology (clear cell vs. serous,
SDHR, 1.68; 95 % CI, 1.14–2.48, and others vs. serous,
SDHR, 2.36; 95 % CI, 1.67–3.34), and type of chemother-
apy (intraperitoneal vs. intravenous chemotherapy, SDHR,
0.82; 95 % CI, 0.70–0.96). Hence intraperitoneal chemo-
therapy remains a significant factor after multivariable
regression modelling in competing risk analysis.
For OCM, two factors demonstrate statistically signifi-
cant which include age and Charlson comorbidity index
in the univariable analysis. After multivariable regression
modelling, these two factors still remain as an independ-
ent factor: age (per 10 years increment, SDHR, 092; 95 %
CI, 0.87–0.97) and Charlson comorbidity index (≥1 vs. 0,
SDHR, 0.79; 95 % CI, 0.66–0.94).
Lastly we conducted a sensitivity analysis for CSM.
Consistent results of subdistribution hazard ratio of intra-
peritoneal chemotherapy vs. intravenous chemotherapy
were obtained when extreme values of the propensity
score were trimmed at different levels − a procedure
shown to partly compensate for unobserved confounding
(Table 3).
Discussion
This competing risks analyses based on a single-
institution database of patients with stage III-IV epithelial
ovarian, tubal, and peritoneal cancer with minimal re-
sidual disease demonstrate better survival outcome treated
Fig. 2 Curves for cumulative incidence function for each histologic subtype
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by intraperitoneal chemotherapy compared to intravenous
chemotherapy with respect to CSM. Intraperitoneal
chemotherapy has been investigated for a long time, and
based on the positive results from a meta-analysis
conducted by National Cancer Institute (NCI) and the
Gynecologic Oncology Group, the NCI has released a
clinical announcement encouraging the gynecological
oncology community to consider intraperitoneal chemo-
therapy using cisplatin as the standard treatment for
advanced ovarian cancer patients in whom the residual
disease were debulked to 1 cm or less [22]. The results of
the current work can further consolidate the role of
Table 2 Results of the subdistribution hazard regression (Fine








Agea 0.96 (0.75–1.23) 0.121 0.95 (0.67–1.35) 0.132
Stage
III 1 1
IV 2.43 (1.58–3.73) 0.026 2.66 (1.47–4.81) 0.021
Grade
1 1 1
2 1.24 (0.97–1.59) 0.037 1.36 (0.99–1.94) 0.088
3 1.57 (1.03–2.39) 0.024 1.89 (1.04–3.43) 0.031
Histology
Serous 1 1
Mucinous 0.93 (0.82–1.05) 0.095 0.95 (0.79–1.14) 0.118
Clear cell 1.43 (1.02–2.01) 0.036 1.68 (1.14–2.48) 0.029
Endometrioid 0.96 (0.82–1.12) 0.102 0.98 (0.89–1.07) 0.095




intraperitoneal 0.78 (0.67–0.91) 0.029 0.82 (0.70–0.96) 0.031
GOG
performance status
≤ 1 1 1




≥ 1 0.84 (0.68–1.04) 0.083 0.88 (0.70–1.09) 0.089
OCM
Agea 0.95 (0.91–0.99) 0.038 0.92 (0.87–0.97) 0.017
Stage
III 1 1
IV 0.92 (0.77–1.11) 0.337 0.87 (0.69–1.04) 0.214
Grade
1 1 1
2 0.87 (0.65–1.16) 0.298 0.91 (0.64–1.29) 0.348
3 0.92 (0.59–1.47) 0.361 0.87 (0.55–1.37) 0.229
Histology
Serous 1 1
Mucinous 1.06 (0.89–1.26) 0.139 1.07 (0.85–1.35) 0.168
Clear cell 1.01 (0.76–1.18) 0.106 1.05 (0.86–1.28) 0.143
Endometrioid 0.95 (0.82–1.10) 0.295 0.98 (0.79–1.21) 0.315
Othersd 0.91 (0.81–1.02) 0.082 0.89 (0.75–1.05) 0.091
Table 2 Results of the subdistribution hazard regression (Fine




Intraperitoneal 0.89 (0.73–1.22) 0.127 0.94 (0.81–1.09) 0.115
GOG
performance status
≤ 1 1 1




≥ 1 0.77 (0.65–0.92) 0.022 0.79 (0.66–0.94) 0.027
Abbreviations CSM cancer-specific mortality, OCM other-cause mortality,
CI confidence interval
aper 10 year increment in age
bSDHR denotes subdistribution hazards ratio obtained by Fine-Gray model.
CI, confidence interval
cAdjusted for the following factors: age, stage, nuclear grade, histologic
subtype, type of chemotherapy
d“Others” histology includes mixed type, undifferentiated, and carcinosarcoma
Table 3 Sensitivity analysis of estimated subdistribution hazard
ratio for CSM by removing a specific percent of cases at the
extremes of propensity scorea
% of PS values trimmed Nc SDHR 95 % CI P
0b 548 0.82 0.70–0.96 0.014
1 514 0.81 0.79–0.81 <0.001
3 472 0.79 0.67–0.93 0.005
5 428 0.79 0.66–0.92 0.004
10 364 0.77 0.64–0.93 0.006
15 248 0.75 0.60–0.94 0.012
20 196 0.72 0.53–0.98 0.036
25 128 0.76 0.61–0.95 0.014
Abbreviations CI confidence interval, CSM cancer-specific mortality, PS propensity
score, SDHR subdistribution hazards ratio
aThe results demonstrates stability of subdistribution hazard ratio across
the iterations
bThe "0 %" trim indicates limiting the analysis to the region of propensity
score overlap
cN indicates number of patients remaining in the analysis
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intraperitoneal chemotherapy in the treatment of ad-
vanced ovarian cancer.
Competing risks methods are common in biomedical
research, particularly in cancer, where the need to deal
with multiple potential outcomes is nearly ubiquitous. In
fact, the concept of competing risks within clinical re-
search was first introduced in the field of oncology [23].
As treatment for cancer produced prolonged survival
times, it became important to consider not only the
effects of treatment on cancer-free survival, but also
how competing risks, such as mortality from unrelated
causes, might impact treatment decisions. For example,
competing risks methods have been applied in the
analyses of risk factors for breast cancer, either at the
screening or treatment stage that may potentially impact
the decision making [24–27].
Traditionally, when predict the unadjusted probability
of a certain event of interest to occur, one can use the
Kaplan–Meier (KM) method. However, in the presence
of competing risks, using the KM method is problem-
atic. This method can handle only one single event at
one time, and all other events are treated as censored
observations. Further, the complement of the KM
estimate (1 − KM) is interpreted as the cumulative
probability of the event of interest in a hypothetical
world where no subject would experience the competing
event. This kind of interpretation is not realistic in
clinical practice [28].
While for the adjusted analysis of competing risk, Fine
and Gray proposed a regression modeling applied
directly on a cumulative incidence function for particu-
lar use in the competing risk analysis. For any event
type, this approach focuses on the hazard associated
with the cumulative incidence function.
Several limitations merit consideration in the
current work. First, the composition of the initial co-
hort may be influenced by referral bias because of the
monocentric design. The index hospital is a tertiary
referral center with more patients harboring co-
morbidities. Thus, the results of the present study
may not be generalizable to the general population.
Second, lack of laboratory data may influence the
robustness of the results. For example, serum cancer
antigen 125 (CA125) is widely used in ovarian cancer
to monitor the effectiveness of therapy both in first
line and recurrence [29, 30]. Lack of inclusion of
CA125 into the calculation of propensity-score may
`bias our results. Third, limitations in patient-level
data collection were also present. For example, socio-
economic status have been found to be associated
with cancer mortality [31] yet, our database did not
capture this important factor which potentially affects
the reliability of both propensity-score and competing
risk modelling. Fourth, the protocol of follow-up was
not strictly defined and censoring recordings may not
be reflective of the true status. Fifth, the current ana-
lysis have not been validated with an external dataset
which limit its clinical application.
Competing risks analyses allow disentangling the
contribution of an intervention (e.g., intraperitoneal
chemotherapy) on each event type separately. Intra-
peritoneal chemotherapy clearly shows therapeutic
benefit in terms of CSM, but not OCM in the current
work. In addition to intraperitoneal chemotherapy,
stage IV (vs. III), grade 3 (vs. grade 1), and clear cell
subtype (vs. serous subtype) also demonstrate as
significant risk factors. Clear cell carcinoma accounts
for 4 to 12 % of epithelial ovarian cancer in Western coun-
tries. Compared to serous adenocarcinoma, clear cell
carcinoma is relatively resistant to conventional platinum,
or taxane-based chemotherapy which is associated with
its poor prognosis [32]. The results of our work sug-
gest that novel therapy should be developed for clear
cell carcinoma in order to improve survival outcome.
From published reports, the mean or median age
for ovarian cancer is between 55 and 60 years which
implies that a significant proportion of patients are
facing the problem of aging. During the course of treat-
ment for cancer, the increased age and co-morbidities of
older patients occasionally lead to death by the occurrence
of competing events (e.g., stroke, infection, and accident).
Clinical studies are often faced with the difficult problem
of how to account for participants who die without experi-
encing the study outcome of interest. Conventional ap-
proaches to describe risk of disease like Kaplan-Meier
survival analysis and Cox proportional hazards regression
can overestimate risk of disease by failing to account for
the competing risk of death [33].
Conclusions
In conclusion, results from this competing risk
analysis provide supportive evidence for previous
published randomized trials that intraperitoneal
chemotherapy outperforms intravenous chemother-
apy. We propose that implementation of competing
risk analysis should be highly considered for the investi-
gation of ovarian cancer patients who have medium to
long-term follow-up period.
Additional file
Additional file 1: Dataset for computing competing risks. (CSV 18 kb)
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CSM: cancer-specific mortality; IP: intraperitoneal; IV: intravenous;
OCM: other-cause mortality.
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